United States Allergy Treatment Market Overview, 2030

The allergy treatment sector in the United States has undergone major changes, influenced by rising allergy cases and progress in therapeutic options. The growing occurrence of food allergies, seasonal reactions, respiratory issues, and skin irritations has heightened the demand for effective and easy-to-access treatments. The Asthma and Allergy Foundation of America AAFA reports that over 50 million Americans face various allergies each year, making these some of the most frequent chronic health issues in the nation. Traditionally, the market was led by antihistamines, decongestants, and corticosteroids as primary treatments, but their shortcomings in providing long-term results have opened doors for innovative therapies like immunotherapy and biologic medications. Immunotherapy, which includes both subcutaneous and sublingual methods, has become increasingly popular for its capacity to tackle the underlying causes of allergic responses, granting patients enduring relief instead of just short-term alleviation of symptoms. Drug development driven by biotechnology has brought forth monoclonal antibodies like omalizumab, targeting immune pathways effectively. The shift in treatment options has also benefitted from the rise of digital healthcare, which has improved diagnosis, personalized treatment, and patient adherence through telehealth and online pharmacy services. The supply dynamics in the U.S. are also changing hospital pharmacies still play a crucial role for advanced treatments, yet retail pharmacies and online platforms are growing swiftly to satisfy consumer needs for convenience. Rising awareness campaigns and government health programs have contributed to lowering underdiagnosis rates and promoting early treatment. Increasing healthcare spending, along with expanded insurance coverage, has made advanced therapies more widely available. Looking ahead, the market is set for more growth as research and development pipelines introduce new treatments, including allergen-specific vaccines and next-generation biologics. The U.S. remains a leader in innovation and adoption within the global allergy treatment landscape, supported by significant global pharmaceutical companies, comprehensive clinical studies, and a vast patient population.

According to the research report, ""US Allergy Treatment Market Overview, 2030,"" published by Bonafide Research, the US Allergy Treatment market is anticipated to grow at more than 5.14% CAGR from 2025 to 2030. This upward trend mirrors the rising occurrence of allergic ailments, changing consumer demands, and continuous advancements in treatment technologies. The increasing prevalence of allergies mainly food, skin, respiratory, and seasonal varieties has led to a significant need for both immediate symptom relief and enduring solutions. Changes in lifestyle, urban growth, and environmental issues like escalating pollution rates have also contributed to a higher frequency of allergic episodes among various age demographics. Advancements in pharmaceuticals are a crucial factor driving this market growth. Treatments for allergies, such as antihistamines, corticosteroids, and decongestants, still hold a major position in prescriptions, but there is a clear movement towards immunotherapy and biologic treatments. Immunotherapy, whether injected or taken under the tongue, is receiving more approval for its potential to address the root causes of allergies. Biologics like monoclonal antibodies such as omalizumab and dupilumab are gaining traction among patients suffering from severe or long-term allergic issues. The increasing focus on personalized healthcare and targeted therapies is allowing medical professionals to customize treatments according to specific patient requirements, enhancing outcomes and adherence. Moreover, distribution patterns contribute positively to market growth. While hospital pharmacies remain vital for complicated therapies, retail and online pharmacies are growing rapidly, thanks to the convenience and improved accessibility for patients. The rise of telemedicine in the United States has improved interactions between patients and doctors, facilitating quicker allergy diagnoses and more straightforward prescription processes. Regulatory approvals, continuous research and development investments, and the expansion of insurance coverage are also promoting market growth by making advanced treatments easier to reach and more affordable.

The market for allergy treatments in the United States i by type is divided into Eye Allergy, Skin Allergy, Food Allergy and Other Allergies which is primarily influenced by food and skin allergies, while seasonal triggers and eye allergies are also boosting patient demand. Food allergies are one of the most urgent issues, impacting around 32 million individuals in America, with a noteworthy number being children. The most prevalent allergies include those to peanuts, tree nuts, shellfish, and dairy, which often necessitate careful dietary restrictions, accessible emergency epinephrine, and continuous advancements in treatment like oral immunotherapy. The rise in awareness and identification of food allergies has led to an increased demand for both preventative measures and urgent care approaches, establishing this sector as the largest in terms of market share. Skin allergies constitute another key area, with ailments like eczema, atopic dermatitis, and contact dermatitis impacting millions of both adults and children in the U.S. The need for corticosteroids, topical antihistamines, and newer biologics, such as dupilumab, has increased notably. Growing environmental irritants and lifestyle changes have further accelerated this sector's expansion, with biologics providing more specialized solutions for ongoing cases. Although smaller in market share, eye allergies are growing swiftly due to a high rate of pollen-induced allergic conjunctivitis, particularly during the spring and fall months. Rising urban pollution and time spent on screens are also exacerbating eye irritation and allergy occurrences. Demand for both over-the-counter antihistamine eye drops and prescribed treatments is increasing, contributing to consistent growth in this sector. Seasonal and respiratory allergies, such as hay fever and allergic rhinitis, remain significant market factors. The mix of antihistamines, decongestants, and immunotherapy options means this area is among the most commonly treated in clinical settings. These sectors demonstrate how various allergy triggers influence the U.S. market.

In the United States, by treatment type is divided into Anti-Allergy Drugs and Immunotherapy medications for allergies are typically the primary option, yet there is a swift increase in the use of immunotherapy for lasting relief. The most common treatments include antihistamines, corticosteroids, leukotriene receptor antagonists, mast cell stabilizers, and decongestants, largely favored for their prompt relief and wide accessibility. Over-the-counter antihistamines like cetirizine and loratadine are frequently utilized for mild allergic responses and seasonal allergies, while prescriptions for corticosteroids are used for more serious respiratory and skin issues. This category is prevalent due to its low cost, convenience from both physical and online pharmacies, and the quick relief offered to users. Nonetheless, these medications mainly alleviate symptoms instead of tackling the underlying causes of allergies, which limits their long-term effectiveness. Conversely, immunotherapy is becoming more popular as a groundbreaking treatment approach. Subcutaneous immunotherapy, known as allergy shots, and sublingual immunotherapy, delivered via tablets or drops, are increasingly being recommended for individuals with ongoing or severe allergic issues. Different from traditional medications, immunotherapy gradually conditions the immune system to cope with particular allergens, providing a disease-modifying effect that not only minimizes symptoms over time but may also avert the emergence of new allergies or asthma. In America, the uptake of immunotherapy is growing due to increased awareness among healthcare providers, compelling clinical data, and rising patient interest in long-lasting solutions. Moreover, advanced biologics like omalizumab and dupilumab, categorized as targeted immunotherapies, are being integrated for conditions such as severe asthma and atopic dermatitis, indicating a move toward more precise medical treatments. These two treatment categories define the market in the U.S. anti-allergy drugs hold the largest market share due to their ready availability and immediate response, while immunotherapy is progressively transforming the segment with its long-term advantages.

In the U.S. allergy treatment sector, by distribution channel is divided into Hospital Pharmacies, Retail Pharmacies, Online Retailers and Others but the hospital pharmacies are at the forefront, yet retail and online pharmacies are seeing a quick rise in popularity due to their convenience. Hospital pharmacies maintain their leading position because they offer sophisticated allergy solutions, such as prescription-only biologics and injectable immunotherapies. Patients who suffer from serious issues like atopic dermatitis, allergy-related asthma, or chronic food intolerances often need care supervised by hospitals, which underscores the importance of hospital pharmacies for specialized therapies. Their significance is further enhanced by the collaboration with allergy specialists within hospital settings, where complicated cases necessitate careful observation and distribution of high-value medications. On the other hand, retail pharmacies capture a notable portion of the U.S. allergy treatment market. Major chains like CVS, Walgreens, and Walmart provide easy access to non-prescription antihistamines, corticosteroid nasal sprays, and eye drops, appealing to the vast number of individuals experiencing mild to moderate allergies. These pharmacies also offer prescription refills, consultations with pharmacists, and loyalty programs, which enhance their outreach and credibility with customers. Given that allergies rank among the most prevalent chronic ailments in the U.S., the convenience offered by retail pharmacies makes them a favored option for regular allergy care. Moreover, online pharmacies are rapidly expanding, driven by the growth of e-commerce and telehealth services. Patients are increasingly purchasing both prescription and OTC medications via the internet due to factors such as time efficiency, home delivery, and lower prices. Digital health platforms have expedited this shift by allowing virtual consultations and direct e-prescriptions, making online pharmacies a transformative presence in the distribution landscape. Other distribution methods, including specialty drug distributors and mail-order services, also contribute to the range of options available, particularly for chronic allergy sufferers needing ongoing medication.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Allergy Care Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Type
• Eye Allergy
• Skin Allergy
• Food Allergy
• Other Allergies

By Treatment Type
• Anti-Allergy Drugs
• Immunotherapy

By Distribution Channels
• Hospital Pharmacies
• Retail Pharmacies
• Online Retailers
• Others Show more